Hannah M Hollandsworth1, Thinzar M Lwin1, Siamak Amirfakhri1, Filemoni Filemoni2, Surinder K Batra3, Robert M Hoffman2, Punita Dhawan3, Michael Bouvet4. 1. Department of Surgery, University of California San Diego, La Jolla, California; Moores Cancer Center, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California. 2. Department of Surgery, University of California San Diego, La Jolla, California; Moores Cancer Center, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California; AntiCancer, Inc, San Diego, California. 3. Department of Biochemistry, University of Nebraska Medical Center, Omaha, Nebraska. 4. Department of Surgery, University of California San Diego, La Jolla, California; Moores Cancer Center, University of California San Diego, La Jolla, California; Department of Surgery, VA San Diego Healthcare System, San Diego, California. Electronic address: mbouvet@ucsd.edu.
Abstract
INTRODUCTION: Claudins are tight-junction proteins, which maintain an epithelial barrier in normal colon cells. Overexpression of Claudin-1 has been implicated for development of colon cancer. We postulated that Claudin-1 may be a useful target in near-infrared imaging and fluorescence-guided surgery. METHODS: We conjugated Claudin-1 antibody to LI-COR IR800DyeCW (Claudin-1-IRDye800CW). Western blotting of 9 human colon cancer cell lysates was performed. Animal imaging was performed with the LI-COR Pearl Trilogy Fluorescence Imaging System. A dose-response study was carried out with subcutaneous LS174T colon cancer cell line models. Increasing doses of Claudin-1-IRDye800CW via tail vein injection were administered to three groups of mice. Two groups of mice were used as controls (antibody alone, and dye alone). In vivo imaging was performed at 24, 48, and 72 h after administration of the conjugated dye. Orthotopic implantation of patient-derived tumors and cell lines was performed and peritoneal carcinomatosis models were created. After tumor growth, mice were administered Claudin-1-IRDye800CW and imaged in vivo 48 h later. The mice were euthanized and laparotomy was performed to assess internal organs and toxicity. RESULTS: Western blotting revealed that all colon cancer cell lysates expressed varying amounts of Claudin-1. All tumors demonstrated strong and specific fluorescence labeling at 800 nm, even with the lowest dose of 12.5 μg of Claudin-1-IRDye800CW. CONCLUSIONS: Claudin-1 is a useful target for near-infrared antibody-based imaging for visualization of colorectal tumors for future use in fluorescence-guided surgery. Published by Elsevier Inc.
INTRODUCTION: Claudins are tight-junction proteins, which maintain an epithelial barrier in normal colon cells. Overexpression of Claudin-1 has been implicated for development of colon cancer. We postulated that Claudin-1 may be a useful target in near-infrared imaging and fluorescence-guided surgery. METHODS: We conjugated Claudin-1 antibody to LI-COR IR800DyeCW (Claudin-1-IRDye800CW). Western blotting of 9 humancolon cancer cell lysates was performed. Animal imaging was performed with the LI-COR Pearl Trilogy Fluorescence Imaging System. A dose-response study was carried out with subcutaneous LS174T colon cancer cell line models. Increasing doses of Claudin-1-IRDye800CW via tail vein injection were administered to three groups of mice. Two groups of mice were used as controls (antibody alone, and dye alone). In vivo imaging was performed at 24, 48, and 72 h after administration of the conjugated dye. Orthotopic implantation of patient-derived tumors and cell lines was performed and peritoneal carcinomatosis models were created. After tumor growth, mice were administered Claudin-1-IRDye800CW and imaged in vivo 48 h later. The mice were euthanized and laparotomy was performed to assess internal organs and toxicity. RESULTS: Western blotting revealed that all colon cancer cell lysates expressed varying amounts of Claudin-1. All tumors demonstrated strong and specific fluorescence labeling at 800 nm, even with the lowest dose of 12.5 μg of Claudin-1-IRDye800CW. CONCLUSIONS:Claudin-1 is a useful target for near-infrared antibody-based imaging for visualization of colorectal tumors for future use in fluorescence-guided surgery. Published by Elsevier Inc.
Authors: Punita Dhawan; Amar B Singh; Natasha G Deane; Yiran No; Sheng-Ru Shiou; Carl Schmidt; John Neff; M Kay Washington; R Daniel Beauchamp Journal: J Clin Invest Date: 2005-06-16 Impact factor: 14.808
Authors: Kiranya E Tipirneni; Jason M Warram; Lindsay S Moore; Andrew C Prince; Esther de Boer; Aditi H Jani; Irene L Wapnir; Joseph C Liao; Michael Bouvet; Nicole K Behnke; Mary T Hawn; George A Poultsides; Alexander L Vahrmeijer; William R Carroll; Kurt R Zinn; Eben Rosenthal Journal: Ann Surg Date: 2017-07 Impact factor: 12.969
Authors: Amar B Singh; Ashok Sharma; J Joshua Smith; Moorthy Krishnan; Xi Chen; Steven Eschrich; Mary K Washington; Timothy J Yeatman; R Daniel Beauchamp; Punita Dhawan Journal: Gastroenterology Date: 2011-08-28 Impact factor: 22.682
Authors: Ali A Maawy; Yukihiko Hiroshima; Yong Zhang; Roger Heim; Lew Makings; Miguel Garcia-Guzman; George A Luiken; Hisataka Kobayashi; Robert M Hoffman; Michael Bouvet Journal: PLoS One Date: 2015-03-23 Impact factor: 3.240
Authors: Emily F Rabinsky; Bishnu P Joshi; Asha Pant; Juan Zhou; Xiyu Duan; Arlene Smith; Rork Kuick; Shuling Fan; Asma Nusrat; Scott R Owens; Henry D Appelman; Thomas D Wang Journal: Cell Mol Gastroenterol Hepatol Date: 2015-12-13
Authors: Ryan K Orosco; Viridiana J Tapia; Joseph A Califano; Bryan Clary; Ezra E W Cohen; Christopher Kane; Scott M Lippman; Karen Messer; Alfredo Molinolo; James D Murphy; John Pang; Assuntina Sacco; Kathryn R Tringale; Anne Wallace; Quyen T Nguyen Journal: Sci Rep Date: 2018-04-09 Impact factor: 4.379
Authors: Thinzar M Lwin; Kentaro Miyake; Takashi Murakami; Jonathan C DeLong; Siamak Amirfakhri; Filemoni Filemoni; Sang Nam Yoon; Paul J Yazaki; John E Shivley; Brian Datnow; Bryan M Clary; Robert M Hoffman; Michael Bouvet Journal: Oncotarget Date: 2018-12-18
Authors: Hannah M Hollandsworth; Siamak Amirfakhri; Filemoni Filemoni; Robert M Hoffman; Justin Molnar; Paul J Yazaki; Michael Bouvet Journal: J Surg Res Date: 2020-03-24 Impact factor: 2.192
Authors: Frank A E Kruyt; Rob J M Groen; Bianca M Dijkstra; Marion de Jong; Marcus C M Stroet; Fritz Andreae; Sebastiaan E Dulfer; Marieke Everts; Schelto Kruijff; Julie Nonnekens; Wilfred F A den Dunnen Journal: J Neurooncol Date: 2021-03-26 Impact factor: 4.130
Authors: Ajaz A Bhat; Najeeb Syed; Lubna Therachiyil; Sabah Nisar; Sheema Hashem; Muzafar A Macha; Santosh K Yadav; Roopesh Krishnankutty; Shanmugakonar Muralitharan; Hamda Al-Naemi; Puneet Bagga; Ravinder Reddy; Punita Dhawan; Anthony Akobeng; Shahab Uddin; Michael P Frenneaux; Wael El-Rifai; Mohammad Haris Journal: Int J Mol Sci Date: 2020-01-15 Impact factor: 5.923